Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Contrafect (NQ: CFRX )

3.730 USD -0.100 (-2.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 92,147
Open 3.800
Bid (Size) 3.750 (2)
Ask (Size) 3.770 (3)
Prev. Close 3.830
Today's Range 3.710 - 3.830
52wk Range 3.100 - 7.630
Shares Outstanding 39,332,721
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021
Data Being Presented Demonstrates Directly Positive Clinical Utility and Furthers the Understanding of Exebacase in Treating Staphylococcus aureus Bacteremia, Including Multidrug-Resistant MRSA 
From GlobeNewswire News Releases
ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference
From GlobeNewswire News Releases

Performance

YTD
-29.22%
-29.22%
1 Month
-12.85%
-12.85%
3 Month
-4.85%
-4.85%
6 Month
-13.86%
-13.86%
1 Year
-28.27%
-28.27%

More News

Read More
ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update
From GlobeNewswire News Releases
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
From GlobeNewswire News Releases
ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity
From GlobeNewswire News Releases
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development
From GlobeNewswire News Releases
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum
From GlobeNewswire News Releases
Imvax Further Strengthens Leadership Team with Appointment of Josh Muntner as Chief Financial Officer
From Business Wire News Releases
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections
From GlobeNewswire News Releases
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
From GlobeNewswire News Releases
We Did The Math FDM Can Go To $76
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.